Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 4:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 2,317 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PET (Positron Emission Tomography) Clear all
Completed Not applicable Interventional Results available

Comparison of Yttrium-90 Absorbed Doses Using PET/CT Versus PET/MR Imaging for Hepatic Malignancies

NCT04332419
View directory record Official record
Conditions
Hepatic Malignancies
Interventions
PET/CT, PET/MR, SIRT with Y-90
Device · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Oct 14, 2026, 4:05 AM EDT
Not listed Phase 2 Interventional

Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies

NCT05013099
View directory record Official record
Conditions
Melanoma, Merkel Cell Carcinoma, Unspecified, Renal Cell Carcinoma, Non Small Cell Lung Cancer
Interventions
zirconium Zr 89 crefmirlimab berdoxam
Biological
Lead sponsor
ImaginAb, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Little Rock, Arkansas • Duarte, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Oct 14, 2026, 4:05 AM EDT
Completed Early Phase 1 Interventional

Anti-1-amino-3-[18F]Fluorocyclobutyl-1-carboxylic Acid (Anti-[18F](FACBC)Positron Emission Tomography (PET-CT) of the Breast

NCT01659645
View directory record Official record
Conditions
Breast Cancer
Interventions
FACBC
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Oct 14, 2026, 4:05 AM EDT
Terminated No phase listed Observational

Use of PET-CT in the Management of Crohn's Disease

NCT01182467
View directory record Official record
Conditions
Crohn's Disease
Interventions
PET-CT scan
Radiation
Lead sponsor
Columbia University
Other
Eligibility
21 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2015 · Synced Oct 14, 2026, 4:05 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma

NCT00086801
View directory record Official record
Conditions
Lymphoma
Interventions
doxorubicin hydrochloride, gemcitabine hydrochloride, vinblastine, fludeoxyglucose F 18 positron-emission tomography (PET) scan, CT scan
Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
16 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
47
States / cities
San Francisco, California • Lewes, Delaware • Newark, Delaware + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2016 · Synced Oct 14, 2026, 4:05 AM EDT
Withdrawn Phase 2 Interventional

CPC-201 Alzheimer's Disease Type Dementia: PET Study

NCT02860065
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
CPC-201, Positron emission tomography (PET)
Drug · Other
Lead sponsor
Chase Pharmaceuticals Corporation, an affiliate of Allergan plc
Industry
Eligibility
50 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
West Bloomfield, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Oct 14, 2026, 4:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy

NCT01806675
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Male Breast Cancer, Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Adult Brain Tumor, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Colon Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Hypopharyngeal Cancer, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Laryngeal Cancer, Recurrent Lip and Oral Cavity Cancer, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Nasopharyngeal Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Oropharyngeal Cancer, Recurrent Pancreatic Cancer, Recurrent Paranasal Sinus and Nasal Cavity Cancer, Recurrent Rectal Cancer, Recurrent Renal Cell Cancer, Recurrent Salivary Gland Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Pancreatic Cancer, Stage IV Renal Cell Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVA Salivary Gland Cancer, Stage IVB Colon Cancer, Stage IVB Salivary Gland Cancer, Stage IVC Salivary Gland Cancer, Tongue Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2
Drug
Lead sponsor
Sanjiv Sam Gambhir
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Oct 14, 2026, 4:05 AM EDT
Completed Not applicable Interventional Results available

Cryotherapy in Treating Patients With Primary Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery

NCT00303901
View directory record Official record
Conditions
Lung Cancer, Metastatic Cancer
Interventions
cryosurgery, positron emission tomography
Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Oct 14, 2026, 4:05 AM EDT
Terminated Phase 1 Interventional

Next Generation Personalized Neuroblastoma Therapy

NCT02780128
View directory record Official record
Conditions
Neuroblastoma, Cancer
Interventions
Biopsy, Next Generation Sequencing, Tumor Scans, Bone marrow Tests, Physical Exam, Eye Exam, Labs, Pregnancy Test, Interviews, ECG, Echocardiogram, Ribociclib, Ceritinib
Procedure · Genetic · Other + 2 more
Lead sponsor
Yael P Mosse
Other
Eligibility
1 Year to 21 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 14, 2026, 4:05 AM EDT
Suspended Phase 1 Interventional

Study Evaluating 111In-Panitumumab for Nodal Staging in Head and Neck Cancer

NCT04840472
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
111I-n panitumumab, Single photon emission computed tomography/computed tomography (SPECT/CT) scans
Drug · Procedure
Lead sponsor
Stanford University
Other
Eligibility
19 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 14, 2026, 4:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Prospective Image Reevaluation Study to Assess the Efficacy of 18F-mFBG PET Imaging in Subjects With Neuroblastoma

NCT07833631
View directory record Official record
Conditions
Neuroblastoma
Interventions
18F-MFBG
Drug
Lead sponsor
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Industry
Eligibility
Not listed
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Englewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 14, 2026, 4:05 AM EDT
Active, not recruiting Phase 3 Interventional

RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)

NCT05134012
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
[O-15]-Water PET Myocardial Perfusion Imaging (MPI)
Drug
Lead sponsor
MedTrace Pharma A/S
Industry
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Iowa City, Iowa • Rochester, Minnesota • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 14, 2026, 4:05 AM EDT
Active, not recruiting Phase 1 Interventional

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease

NCT03025256
View directory record Official record
Conditions
Acral Lentiginous Melanoma, Central Nervous System Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Leptomeningeal Neoplasm, Melanocytoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Melanoma, Metastatic Mucosal Melanoma, Metastatic Uveal Melanoma, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Lumbar Puncture, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography
Procedure · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 14, 2026, 4:05 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers Results available

Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer

NCT02827877
View directory record Official record
Conditions
HER2 Positive Breast Carcinoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Copper Cu 64-DOTA-Trastuzumab, Laboratory Biomarker Analysis, Pertuzumab, Positron Emission Tomography, Therapeutic Conventional Surgery, Trastuzumab
Radiation · Other · Biological + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 14, 2026, 4:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Measuring Active Microglia in Progressive Multiple Sclerosis

NCT02207075
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis
Interventions
[C11]PK-1195 PET scan
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 14, 2026, 4:05 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

[C-11]PiB PET Imaging in Alcohol Use Disorders

NCT03746366
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
[C-11], Pittsburgh Compound B
Radiation · Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
40 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 14, 2026, 4:05 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

CB1 Receptor PET Imaging Reveals Gender Differences in PTSD

NCT02237677
View directory record Official record
Conditions
Post-traumatic Stress Disorder (PTSD)
Interventions
Positron emission tomography (PET) imaging
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2016 · Synced Oct 14, 2026, 4:05 AM EDT
Recruiting Phase 2 Interventional

Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma

NCT07657312
View directory record Official record
Conditions
Cytokine Release Syndrome, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Infliximab, Positron Emission Tomography, Talquetamab, Teclistamab, X-Ray Imaging
Procedure · Biological · Drug
Lead sponsor
Naresh Bumma
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 14, 2026, 4:05 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain

NCT03080051
View directory record Official record
Conditions
Progressive Supranuclear Palsy, Alzheimer Disease, Healthy Volunteers
Interventions
[18F]MNI-952, [18F]Florbetapir
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
18 Years to 90 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 14, 2026, 4:05 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

[18F]F-DOPA Imaging in Patients With Autonomic Failure

NCT04246437
View directory record Official record
Conditions
Autonomic Failure, Pure Autonomic Failure, Parkinson Disease, Multiple System Atrophy, Dementia With Lewy Bodies
Interventions
[18F]FDOPA, Carbidopa 200mg oral dose, Entacapone 400mg oral dose
Drug
Lead sponsor
Daniel Claassen
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 14, 2026, 4:05 AM EDT
Recruiting Phase 1 Interventional

177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

NCT07145177
View directory record Official record
Conditions
Metastatic Prostate Cancer, Prostate Cancer
Interventions
177Lu-PSMA-617, Ablation, Trans-arterial chemoembolization (TACE), Positron Emission Tomography (PET)/Computerized tomography (CT), Tumor Biopsy, Questionnaire
Drug · Procedure · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 14, 2026, 4:05 AM EDT
Active, not recruiting No phase listed Observational

FDG-PET Imaging in Painful Joint Prosthesis

NCT00194285
View directory record Official record
Conditions
Painful Joint Prostheses
Interventions
FDG-PET Imaging
Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 14, 2026, 4:05 AM EDT
Recruiting Phase 3 Interventional

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

NCT05946213
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, External Beam Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Procedure · Radiation · Other
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
1,209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2041
U.S. locations
402
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Little Rock, Arkansas + 303 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 14, 2026, 4:05 AM EDT
Not yet recruiting Phase 1 Interventional

Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity

NCT07838649
View directory record Official record
Conditions
Lymphoma Cancer, Breast Cancer, Cancer of the Breast, Non-Hodgkin Lymphoma, Hodgkin Lymphoma
Interventions
68Ga-Galmydar, PET/MRI, 18F-FDG
Drug · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
21 Years to 99 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 14, 2026, 4:05 AM EDT